본문 바로가기

business

Anti-cancer Immunotherapy

NKMAX’s immunotherapy is a novel potential treatment that activates
the immune cells in our body to kill the cancer cells.

Anti-cancer immunotherapy has improved the survival rate of cancer patients who hardly reactedwith poor response to the existing treatments and have even been effective against cancer cells that have evaded the immune system.
Anti-cancer immunotherapies can be used as treatments for most types of cancers. Recently, it has been provedn that combining anti-cancer immunotherapies with other cancer treatments or therapies enhances their effectiveness.

Comparison with other Immunotherapies

NK cells are the only immune cells that can detect abnormal cells, including cancer cells, and directly kill them without specific target antigens. Unlike other immune cells, NK cells are quick and effective at finding and destroying target cells.

Item NK Cell Therapy Dendritic Cell (DC) Therapy CAR-T Cell Therapy
Cell type NK Cells Dendritic Cells T-cells
Target Antigens Non-specific Specific Specific
Presence of Antigens None Natural Artificial
Cancer-killing Cells Direct killing Induces T-cell activation Direct killing
Reaction to Cancer Antigens Fast Slow Slow
Safety High High Low (Able to cause cytokine syndrome.)
Culturing process Difficult Easy Easy

Advantages of the novel potential immunotherapy SuperNK

Larger production

NK cells can be multiplied by 1,000 to 10,000 folds through a patented culturing technology.

Change in the Number of NK Cells during the culture

Change in the Number of NK Cells during the culture graph1 Change in the Number of NK Cells during the culture graph2 Change in the Number of NK Cells during the culture graph3

High Purity of NK Cells

The purity of NK cells is increased to 99% through NKMAX’s culturing process.

Comparison of NK Cell Purity before & after Culturing

Comparison of NK Cell Purity before & after Culturing graph

Improved cancer cell killing ability

The culturing process reinforces the ability to kill cancer cells.

Comparison of Cancer Cell killing ability before & after Culturing

  • Comparison of Cancer Cell killing ability before & after Culturing graph1
  • Comparison of Cancer Cell killing ability before & after Culturing graph2
  • Comparison of Cancer Cell killing ability before & after Culturing graph3

Effector cell(Super NK):Target cell(K562 cell line) ratio = 1:1

Improved immune activity

The culturing process reinforces immune function.

Comparison of Cytokine Secretion before & after Culturing

IFN-γ Cytokine graph TNF-α Cytokine graph

Possibility of Combining immunotherapy with target cancer treatment

When SuperNK® immunotherapy is combined with another cancer treatment, NK cells’ cancer killing ability improved.

Comparison of ADCC by Combining Immunotherapy with target cancer treatment

  • Comparison of ADCC by Combining Immunotherapy with target cancer treatment graph1

    Erbitux (Cetuximab) - A549 (Lung Cancer, EGFR+) graph

    Erbitux (Cetuximab) - A431 (Skin Cancer, EGFR+) graph

  • Comparison of ADCC by Combining Immunotherapy with target cancer treatment graph2

    Mabthera (Rituximab) - Romos (Burkitt Lymphoma, CD20+) graph

    Herceptin (Trastuzumab) - AU565 (Breast Cancer, Her2+) graph

ADCC: Antibody-dependent cellular cytotoxicity

Safety

  • Pre-clinical study confirms safety for clinical trials
  • Clinical trial Phase 1/2a for Non-small cell lung cancer : Approved by the Korean FDA on Dec 14, 2018.
  • Clinical trial Phase 1 for Recurrent solid cancers: Approved by the U.S. FDA on Mar 1, 2019.
  • Obtained the Advanced Regenerative Treatment Technology Permit from the Japanese Ministry of Health, Labor, and Welfare’s Regenerative Medicine Committee.

Excellent Anti-cancer Efficacy

Pre-clinical study confirms that SuperNK delays cancer cell growth and inhibits metastasis.

  • Delay of Cancer cell growth

    Outcomes after transplant of gastric cancer graph
  • Prevention of liver metastases in breast cancer

    24 days after transplanting breast cancer

    Super NK injection (n=10) - Large numbers of metastatic spots were observed in the liver

    Super NK injection (n=12) - Almost no metastatic spots were observed in the liver.


Move to Top